Practice of Drug Selection of Eezetimibe and Hybutimibe
OBJECTIVE:To evaluate eezetimibe and hybutimibe,so as to provide evidence for medical institutions to select cholesterol absorption inhibitors.METHODS:According to the Quick Guideline for Drug Evaluation and Selection in Chinese Medical Institutions,quantitative scoring evaluation system was adopted,Wanfang Data,CNKI,VIP,Embase and PubMed databases were searched with reference to drug instructions,diagnosis and treatment specifications,clinical guidelines and expert consensus.Ezetimibe and haberimibe were scored in 10 aspects,including pharmacological properties,efficacy,safety,economy,national health insurance,essential medicines,storage conditions,expiration date of the drug,global use,and status of the manufacture,and the level of recommendation was classified according to the scores.RESULTS:Final scores of eezetimibe and hybutimibe were 72.4 and 67.6 points,respectively.Both drugs were cholesterol absorption inhibitors and had unique advantages in the treatment of hypercholesterolemia.Ezetimibe,as a classical drug,was recommended by many guidelines as a first-tier drug.Habermeibe,as a new drug,was slightly better in terms of safety and economy of long-term use.CONCLUSIONS:Ezetimibe and haberimibe have their own advantages in different attributes,and this drug selection may provide an evidence-based basis for healthcare organizations.
Drug selectionCholesterol absorption inhibitorEezetimibeHybutimibeHypercholesterolemia
万方数据
维普
